OR WAIT null SECS
Patricia Van Arnum was executive editor of Pharmaceutical Technology.
February 16, 2006
Informex, ORLANDO - Facing growing competition from offshore suppliers, several mid-sized custom manufacturers announced expansion plans in specialized technologies at Informex this week.
Informex, ORLANDO - Saltigo GmbH (Leverkusen, Germany, www.saltigo.com), newly formed from the fine chemicals business unit of Lanxess AG (Leverkusen, Germany, www.lanxess.com), made its debut at Informex in Orlando this week. Saltgio will officially launch as a new company in April. It will focus on custom manufacturing and be divided into three principal business lines: pharmaceuticals, specialties, and agrochemicals.
Informex, ORLANDO - Optimizing a synthesis for an active pharmaceutical ingredient (API) or pharma intermediate is a critical part of the pharmaceutical manufacturing process, and several exhibitors at this year’s Informex highlighted their recent advances in catalysis, biocatalysis, and chiral chemistry. Among the developments: Reaxa to launch biotech affiliate. ChiralQuest develops new chiral ligands. BioCatalytics launches new line. Codexis expands directed evolution biocatalysis program with BMS. Chemtura targets organometallic catalysts for pharma manufacturing.
February 09, 2006
The US Securities and Exchange Commission (SEC) has ended its investigation of whether Chiron Corporation (Emeryville, CA, www.chiron.com) violated federal security laws in connection with the previous suspension of Chiron’s license to manufacture “Fluvirin” influenza virus vaccine by the UK Medicines and Healthcare Products Regulatory Agency.
Akzo Nobel NV (Arnhem, the Netherlands, www.akzonobel.com) plans to spin off its pharmaceutical division by creating a separate company, Organon Biosciences.
Cambrex Corporation (East Rutherford, NJ, www.cambrex.com), a contract manufacturer and provider of life sciences products and services, has retained Bear Sterns & Co Inc. as an advisor as it considers strategic alternatives for the company.